Association of a (TTTA)_n microsatellite and a TCT del/ins polymorphisms in the aromatase gene (CYP19) with hip fracture risk in Mexican postmenopausal women

References

• Polymeropoulos MH, Xiao H, Rath DS, Merril CR. Tetranucleotide repeat polymorphism at the human aromatase cytochrome P-450 gene (CYP19). Nucleic Acids Res 1991;19:195
   PubMed Web of Science ®Google Scholar
• Masi L, Becherini L, Gennari L, et al. Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. J Clin Endocrinol Metab 2001;86:2263–9
   PubMed Web of Science ®Google Scholar
• Tofteng CL, Kindmark A, Brandstrom H, et al. Polymorphisms in the CYP19 and AR genes–relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: the Danish Osteoporosis Prevention Study. Calcif Tissue Int 2004;74:25–34
   PubMed Web of Science ®Google Scholar
• Masi L, Ottanelli S, Berni R, et al. CYP19 and ESR1 gene polymorphisms: response of the bone mineral density in post-menopausal women to hormonal replacement therapy. Clin Case Miner Bone Metabol 2014;11:36–43
   PubMedGoogle Scholar
• Markatseli AE, Lazaros L, Markoula S, et al. Association of the (TTTA)n repeat polymorphism of CYP19 gene with bone mineral density in Greek peri- and postmenopausal women. Clin Endocrinol 2014;81:38–44
   PubMed Web of Science ®Google Scholar
• Zarrabeitia A, Zarrabeitia MT, Valero C, et al. Age-related influence of common aromatase gene polymorphisms on bone mass of healthy men. Bone 2004;35:243–8
   PubMed Web of Science ®Google Scholar
• Gennari L, Masi L, Merlotti D, et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab 2004;89:2803–10
   PubMed Web of Science ®Google Scholar
• Salmen T, Heikkinen A-M, Mahonen A, et al. Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women. Ann Med 2003;35:282–8
   PubMed Web of Science ®Google Scholar
• Healey CS, Dunning AM, Durocher F, et al. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 2000;21:189–93
   PubMed Web of Science ®Google Scholar
• Falcón-Ramírez E, Casas-Avila L, Cerda-Flores RM, et al. Association of LRP5 haplotypes with osteoporosis in Mexican women. Mol Biol Rep 2013;40:2705–10
   PubMed Web of Science ®Google Scholar
• Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332:767–73
   PubMed Web of Science ®Google Scholar
• De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005;16:1330–8
   PubMed Web of Science ®Google Scholar
• Armstrong MEG, Spencer EA, Cairns BJ, et al. Million Women Study C. Body mass index and physical activity in relation to the incidence of hip fracture in postmenopausal women. J Bone Miner Res 2011;26:1330–8
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2014;25:2359–81
   PubMed Web of Science ®Google Scholar
• Ran S, Pei Y-F, Liu Y-J, et al. Bivariate genome-wide association analyses identified genes with pleiotropic effects for femoral neck bone geometry and age at menarche. PLoS One 2013;8:e60362
   Google Scholar
• Mendoza-Romo MA, Ramírez-Arriola MC, Velasco-Chávez JF, et al. Parity and menarche as risk factors for osteoporosis in postmenopausal women. Ginecol Obstet Mex 2014;82:75–82
   PubMedGoogle Scholar
• Hillier TA, Rizzo JH, Pedula KL, et al. Nulliparity and fracture risk in older women: the study of osteoporotic fractures. J Bone Miner Res 2003;18:893–9
   PubMed Web of Science ®Google Scholar
• Kauppi M, Heliövaara M, Impivaara O, et al. Parity and risk of hip fracture in postmenopausal women. Osteoporos Int 2011;22:1765–71
   PubMed Web of Science ®Google Scholar
• Ahn E, Lee J, Park YS, et al. Association between delivery at an advanced maternal age and osteoporosis in elderly Korean women. J Bone Miner Metab 2014. [Epub ahead of print]. DOI 10.1007/s00774-014-0630-6
   Google Scholar
• Dick IM, Devine A, Prince RL. Association of an aromatase TTTA repeat polymorphism with circulating estrogen, bone structure, and biochemistry in older women. Am J Physiol Endocrinol Metab 2005;288:E989–95
   PubMed Web of Science ®Google Scholar
• Riancho JA, Zarrabeitia MT, Valero C, et al. Aromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral density. Bone 2005;36:917–25
   PubMed Web of Science ®Google Scholar
• Kastelan D, Grubic Z, Kraljevic I, et al. Decreased peak bone mass is associated with a 3-bp deletion/insertion of the CYP19 intron 4 polymorphism: preliminary data from the GOOS study. J Endocrinol Invest 2007;30:465–9
   PubMed Web of Science ®Google Scholar
• Kastelan D, Grubic Z, Kraljevic I, et al. The role of estrogen receptor-alpha gene TA polymorphism and aromatase gene TTTA polymorphism on peak bone mass attainment in males: is there an additive negative effect of certain allele combinations? J Bone Miner Metab 2009;27:198–204
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim WY, Choi JY, et al. Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population. J Hum Genet 2010;55:189–93
   PubMed Web of Science ®Google Scholar
• Mendoza N, Morón FJ, Saez ME, et al. Weighting the effect of CYP19A gene in bone mineral density of postmenopausal women. Bone 2006;38:951–3
   PubMed Web of Science ®Google Scholar